Bethea's Byte
AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake D5FRa
Welcome to Bethea's Byte. If you are a member, please sign in and participate. If you are not a member, please sign up and join the conversation. We'd love to hear from you.
Bethea's Byte
AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake D5FRa
Welcome to Bethea's Byte. If you are a member, please sign in and participate. If you are not a member, please sign up and join the conversation. We'd love to hear from you.
Bethea's Byte
Would you like to react to this message? Create an account in a few clicks or log in to continue.
WELCOME TO YOUR HOME FOR NEWS, OPINIONS, DEBATES & YOUR VOICE -- BETHEA'S BYTE
Welcome guests and members to the home for News, Opinions, Debates and Your Voice... Bethea's Byte. To all guests of this site, please feel free to look things over, but you are encouraged to register and take part in discussing all news reports posted here. You are also encouraged, as a member to post your own news stories. We would love to have discussions on your news reports as well. You are further encouraged to debate these stories as well, especially in the political areas. All I ask is that no matter what side you're on, keep the debates civil. If you are joining us from another forum, we ask you to affiliate with us. We are more than happy to check you out, join your site and participate with you as well. Once again, you are welcome here at Bethea's Byte. Join in the conversation. Spark a discussion. Have a passionate debate. Most importantly, Let your voice be heard! BYTE THIS!
Log in

I forgot my password

Notifications
    Who is online?
    In total there are 3 users online :: 1 Registered, 0 Hidden and 2 Guests :: 1 Bot

    The Last Outlaw

    [ View the whole list ]


    Most users ever online was 156 on Wed Jul 03, 2019 11:22 am
    Statistics
    We have 33 registered users
    The newest registered user is GamrNrd

    Our users have posted a total of 4299 messages in 1744 subjects
    Latest topics
    » What are your plans for the day
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Yesterday at 3:54 pm by Kyng

    » These 6 Red and Blue States Tell You Everything You Need To Know About Where Delta is Hitting Hardest — And Why
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Tue Jul 27, 2021 8:42 pm by The Last Outlaw

    » Thomas Barrack, Trump Fund-Raiser, Indicted on Lobbying Charge
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Tue Jul 20, 2021 1:10 pm by The Last Outlaw

    » If There's One THing I Can't Stand...
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Sun Jul 11, 2021 9:05 pm by The Last Outlaw

    » Donald Trump Blasts Radical Left for Trying to 'Cancel' July 4 Holiday
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Sun Jul 04, 2021 11:59 am by The Last Outlaw

    » US Hitting Encouraging Milestones on Virus Deaths and Shots
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Sat Jun 26, 2021 4:31 pm by Kyng

    » Tensions Among Democrats Grow Over Israeli-Palestinian Conflict
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Sat May 15, 2021 4:45 pm by The Last Outlaw

    » Here's How Long Derek Chauvin Could Spend in Prison
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Tue Apr 20, 2021 8:37 pm by The Last Outlaw

    » Derek Chauvin Convicted of Murder and Manslaughter in George Floyd's Death
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Tue Apr 20, 2021 5:55 pm by The Last Outlaw

    » 'Wheel of Fortune' Fans Call For Rule Change After Contestant Loses on Minor Technicality
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Thu Apr 08, 2021 3:12 pm by The Last Outlaw

    » Fla. Teacher Who Presented Herself as 'Mother Figure' Accused of Sexually Abusing Student for Years
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Fri Apr 02, 2021 4:15 pm by The Last Outlaw

    » Derek Chauvin Trial: MMA Fighter Who Watched George Floyd's Death Says He Called Police on the Police
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Tue Mar 30, 2021 10:36 am by The Last Outlaw

    » Gun Laws and Stats
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Mon Mar 29, 2021 4:11 pm by The Last Outlaw

    » Floyd Family Kneels Outside Courthouse in Symbolic Statement
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Mon Mar 29, 2021 8:58 am by The Last Outlaw

    » Boulder Shooting: Multiple Injuries, Residents Take Shelter as Police Look For Gunman
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Tue Mar 23, 2021 11:28 am by The Last Outlaw

    » Person of Interest in the Deaths of 5 People, Including Ex-Wife, Allegedly Admits to Murdering 16
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Mon Mar 22, 2021 7:53 pm by The Last Outlaw

    » If You Haven’t Received Your 3rd Stimulus Check Yet, Here’s Why Wednesday Matters
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Mon Mar 22, 2021 6:17 pm by The Last Outlaw

    » Free Byte: What Grinds My Gears? Cancel Culture
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Sun Mar 21, 2021 5:42 pm by Kyng

    » Tennessee Sister and Brother Charged with First-Degree Murder in the Death of Their Disabled Mother
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Sun Mar 21, 2021 5:37 pm by The Last Outlaw

    » Spa Shooting Victims ID'd As Biden, Harris Head To Atlanta
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Clock-10Fri Mar 19, 2021 12:18 pm by The Last Outlaw

    July 2021
    SunMonTueWedThuFriSat
        123
    45678910
    11121314151617
    18192021222324
    25262728293031

    Calendar Calendar

    CBOX
    Affiliate With Bethea’s Byte


    Bethea's Byte

    Anti-Spam Bots!

    Submit Your Site To The Web's Top 50 Search Engines for Free!






    The Coffee House


    Planet Nexus





    IconSkouliki

    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake

    View previous topic View next topic Go down

    The Last Outlaw
    The Last Outlaw
    Male Posts : 1756
    Age : 45
    Join date : 2018-05-25
    Location : Salem, Oregon
    Status :
    Online
    Offline

    http://betheasbyte.com/forum

    PostThe Last Outlaw Thu Nov 26, 2020 5:31 pm

    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake DZRTo

    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake FAzqc

    Rebecca Robbins and Benjamin Mueller of The New York Times wrote:The announcement this week that a cheap, easy-to-make coronavirus vaccine appeared to be up to 90 percent effective was greeted with jubilation. “Get yourself a vaccaccino,” a British tabloid celebrated, noting that the vaccine, developed by AstraZeneca and the University of Oxford, costs less than a cup of coffee.

    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake BB1bmj46

    But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine’s apparently spectacular efficacy will hold up under additional testing.

    Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results.

    Officials in the United States have noted that the results were not clear. It was the head of the flagship federal vaccine initiative — not the company — who first disclosed that the vaccine’s most promising results did not reflect data from older people.

    The upshot, the experts said, is that the odds of regulators in the United States and elsewhere quickly authorizing the emergency use of the AstraZeneca vaccine are declining, an unexpected setback in the global campaign to corral the devastating pandemic.

    “I think that they have really damaged confidence in their whole development program,” said Geoffrey Porges, an analyst for the investment bank SVB Leerink.

    Michele Meixell, a spokeswoman for AstraZeneca, said the trials “were conducted to the highest standards.”

    In an interview on Wednesday, Menelas Pangalos, the AstraZeneca executive in charge of much of the company’s research and development, defended the company’s handling of the testing and its public disclosures. He said the error in the dosage was made by a contractor, and that, once it was discovered, regulators were immediately notified and signed off on the plan to continue testing the vaccine in different doses.

    Asked why AstraZeneca shared some information with Wall Street analysts and some other officials and experts but not with the public, he responded, “I think the best way of reflecting the results is in a peer-reviewed scientific journal, not in a newspaper.”

    AstraZeneca was the third company this month to report encouraging early results on a coronavirus vaccine candidate. At first glance on Monday morning, the results looked promising. Depending on the strength at which the doses were given, the vaccine appeared to be either 90 percent or 62 percent effective. The average efficacy, the developers said, was 70 percent.

    Almost immediately, though, there were doubts about the data.

    The regimen that appeared to be 90 percent effective was based on participants receiving a half dose of the vaccine followed a month later by a full dose; the less effective version involved a pair of full doses. AstraZeneca disclosed in its initial announcement that fewer than 2,800 participants received the smaller dosing regimen, compared with nearly 8,900 participants who received two full doses.

    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake BB1bmmQv

    The biggest questions were, why was there such a large variation in the effectiveness of the vaccine at different doses, and why did a smaller dose appear to produce much better results? AstraZeneca and Oxford researchers said they did not know.

    Crucial information was also missing. The company said that the early analysis was based on 131 symptomatic COVID-19 cases that had turned up in study participants. But it did not break down how many cases were found in each group of participants — those who received the half-strength initial dose, the regular-strength initial dose and the placebo.

    “The press release raised more questions than it answered,” said John Moore, a professor of microbiology and immunology at Weill Cornell Medical College.

    Adding to the confusion, AstraZeneca pooled the results from two differently designed clinical trials in Britain and Brazil, a break from standard practice in reporting the results of drug and vaccine trials.

    “I just can’t figure out where all the information is coming from and how it’s combining together,” said Natalie Dean, a biostatistician and an expert in vaccine trial design at the University of Florida. She wrote on Twitter that AstraZeneca and Oxford “get a poor grade for transparency and rigor when it comes to the vaccine trial results they have reported.”

    With AstraZeneca’s shares declining on Monday, company executives held several private conference calls with industry analysts in which they disclosed details that were not in the public announcement, including how the COVID-19 cases broke down across different groups. Such disclosures to analysts are not uncommon in the industry, but they often generate criticism about why the details were not shared with the public.

    Bigger problems soon surfaced.

    Mr. Pangalos told Reuters on Monday that the company had not intended for any participants to receive the half dose. British researchers running the trial there had meant to give the full dose initially to volunteers, but a miscalculation meant they were mistakenly given only a half dose. Mr. Pangalos described the error as “serendipity,” allowing researchers to stumble onto a more promising dosing regimen.

    To many outside experts, that undercut the credibility of the results because the closely calibrated clinical trials had not been designed to test how well a half-strength initial dose worked.

    The company’s initial announcement didn’t mention the accidental nature of the discovery.

    “The reality is, it could end up being quite a useful mistake,” Mr. Pangalos said in the interview with The New York Times on Wednesday. “It wasn’t putting anyone in danger. It was a dosing error. Everyone was moving very fast. We corrected the mistake and continued on with the study, with no changes to the study, and agreed with the regulator to include those patients in the analysis of the study as well.”

    He added, “What is there to disclose? It actually doesn’t matter whether it was done on purpose or not.”

    In the statement attributed to Oxford, Ms. Meixell, the AstraZeneca spokeswoman, said the error stemmed from an issue, which has since been fixed, with how some of the vaccine doses were manufactured.

    Then, on Tuesday, Moncef Slaoui, the head of Operation Warp Speed, the U.S. initiative to fast-track coronavirus vaccines, noted another limitation in AstraZeneca’s data. On a call with reporters, he suggested that the participants who received the half-strength initial dose had been 55 years old or younger.

    Mr. Pangalos confirmed that on Wednesday, saying the participants received the half-strength dose over a matter of weeks before the error was discovered.

    The fact that the initial half-strength dose wasn’t tested in older participants, who are especially vulnerable to COVID-19, could undermine AstraZeneca’s case to regulators that the vaccine should be authorized for emergency use.

    Stephanie Caccomo, a spokeswoman for the Food and Drug Administration, declined to comment on whether the dosing error would hurt the vaccine’s chances of being authorized. The F.D.A. has said it expects vaccines to be at least 50 percent effective in preventing or reducing the severity of the disease, a bar that the vaccine appears to have cleared even in the group that got the two full doses.

    AstraZeneca’s shares have fallen about 5 percent this week, while broader stock indexes have climbed to record highs. Investors seem to be disappointed with the murky results, especially compared with the much clearer data released by two of AstraZeneca’s chief rivals in the race for a coronavirus vaccine.

    Pfizer and Moderna said this month that their vaccines, which use a technology known as “messenger RNA,” appear to be about 95 percent effective. Both offerings seem nearly certain to win emergency authorization from the F.D.A. in the coming weeks.

    The AstraZeneca vaccine, which uses a different approach involving a chimpanzee virus to provoke an immune response to the coronavirus, had all the hallmarks of a blockbuster.

    It was inexpensive — only a few dollars per dose — and easy to mass-produce. Unlike Pfizer and Moderna’s vaccines, AstraZeneca’s could be stored for months in normal refrigerators. The company has estimated it will be able to produce some three billion doses next year, enough to vaccinate nearly one-fifth of the global population.

    Compared to most of the other leading Covid-19 vaccine developers, AstraZeneca is inexperienced when it comes to vaccines. And even before the chaotic release of results, the company was under scrutiny for its handling of the testing process.

    In September, AstraZeneca paused clinical trials worldwide after a participant fell ill — but the company didn’t promptly announce the decision publicly. AstraZeneca also came under fire for providing details about the nature of the illness on a private conference call with investors hosted by the investment bank J.P. Morgan, rather than disseminating the information to the public. Both of those developments were first reported by STAT, which covers health and science news.

    Ever since the Oxford-AstraZeneca team emerged as front-runners in the race to develop a vaccine this spring, Prime Minister Boris Johnson of Britain has embraced the effort. The government preordered 100 million doses and cast the research as one of the country’s most important contributions to fighting the pandemic.

    Basking in the results on Monday, Mr. Johnson said the vaccine “has the makings of a wonderful British scientific achievement.”

    In the United States, which has ordered at least 300 million doses of AstraZeneca’s vaccine, the regulatory path forward is unclear. AstraZeneca was circumspect on Monday about its plans for seeking regulatory approval. The company said it would seek guidance from the Food and Drug Administration on whether it should formally submit its findings to apply for emergency authorization.

    AstraZeneca has not been testing the promising half-strength initial dose in its ongoing United States trial. The company said it would work with the agency to add it as quickly as possible to that trial.

    Mr. Pangalos said the company is planning a global trial to compare the two dosing regimens. The number of participants it will enroll hasn’t yet been determined, but it will be in the thousands.

    “The only way they’re going to find out is by specifically and deliberately testing this serendipitous observation,” Professor Moore said. “The onus is on them to prove the speculation.”

    It's time for AstraZeneca to own up to strengths and weaknesses when it comes to their vaccine! Let's see what happens, and see if AstraZeneca's vaccine will still be in consideration to help people recover from COVID-19.

    Just Saying.
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake I6goy

    _________________
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake FBCTRAstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake D5SsG
    AstraZeneca Faces Difficult Questions About Its Vaccine After Admitting Mistake Nexads420

    View previous topic View next topic Back to top

    Create an account or log in to leave a reply

    You need to be a member in order to leave a reply.

    Create an account

    Join our community by creating a new account. It's easy!


    Create a new account

    Log in

    Already have an account? No problem, log in here.


    Log in

     
    Permissions in this forum:
    You cannot reply to topics in this forum